136 related articles for article (PubMed ID: 26683465)
1. A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts.
Schueler U; Kaneski C; Remaley A; Demosky S; Dwyer N; Blanchette-Mackie J; Hanover J; Brady R
JIMD Rep; 2016; 29():69-75. PubMed ID: 26683465
[TBL] [Abstract][Full Text] [Related]
2. Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
Tsukimura T; Shiga T; Saito K; Ogawa Y; Sakuraba H; Togawa T
Mol Genet Metab Rep; 2021 Sep; 28():100773. PubMed ID: 34136356
[TBL] [Abstract][Full Text] [Related]
3. ABCA1-dependent mobilization of lysosomal cholesterol requires functional Niemann-Pick C2 but not Niemann-Pick C1 protein.
Boadu E; Nelson RC; Francis GA
Biochim Biophys Acta; 2012 Mar; 1821(3):396-404. PubMed ID: 22179027
[TBL] [Abstract][Full Text] [Related]
4. Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.
Cukier AMO; Therond P; Didichenko SA; Guillas I; Chapman MJ; Wright SD; Kontush A
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):890-900. PubMed ID: 28529180
[TBL] [Abstract][Full Text] [Related]
5. Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.
Katsuta H; Tsuboi K; Yamamoto H; Goto H
Circ J; 2018 Nov; 82(12):3058-3063. PubMed ID: 30282881
[TBL] [Abstract][Full Text] [Related]
6. Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.
Kamani MA; Provençal P; Boutin M; Pacienza N; Fan X; Novak A; Huang TC; Binnington B; Au BC; Auray-Blais C; Lingwood CA; Medin JA
Future Sci OA; 2016 Dec; 2(4):FSO147. PubMed ID: 28116130
[TBL] [Abstract][Full Text] [Related]
7. Lyso-globotriaosylceramide downregulates KCa3.1 channel expression to inhibit collagen synthesis in fibroblasts.
Choi JY; Shin MY; Suh SH; Park S
Biochem Biophys Res Commun; 2015 Dec; 468(4):883-8. PubMed ID: 26592662
[TBL] [Abstract][Full Text] [Related]
8. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
9. Generation of an
Kaneski CR; Hanover JA; Schueler Hoffman UH
Mol Genet Metab Rep; 2022 Jun; 31():100871. PubMed ID: 35782611
[TBL] [Abstract][Full Text] [Related]
10. D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1.
Xie Q; Zhao SP; Li F
Tohoku J Exp Med; 2010 Mar; 220(3):223-8. PubMed ID: 20208418
[TBL] [Abstract][Full Text] [Related]
11. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
[TBL] [Abstract][Full Text] [Related]
12. Globotriaosylceramide-induced reduction of K
Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
[TBL] [Abstract][Full Text] [Related]
13. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
[TBL] [Abstract][Full Text] [Related]
14. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide.
De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
Mol Genet Metab; 2011 Nov; 104(3):319-24. PubMed ID: 21724436
[TBL] [Abstract][Full Text] [Related]
15. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.
Yasuda M; Huston MW; Pagant S; Gan L; St Martin S; Sproul S; Richards D; Ballaron S; Hettini K; Ledeboer A; Falese L; Cao L; Lu Y; Holmes MC; Meyer K; Desnick RJ; Wechsler T
Mol Ther Methods Clin Dev; 2020 Sep; 18():607-619. PubMed ID: 32775495
[TBL] [Abstract][Full Text] [Related]
16. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency.
Marcil M; Yu L; Krimbou L; Boucher B; Oram JF; Cohn JS; Genest J
Arterioscler Thromb Vasc Biol; 1999 Jan; 19(1):159-69. PubMed ID: 9888879
[TBL] [Abstract][Full Text] [Related]
17. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
18. A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients.
Alharbi FJ; Geberhiwot T; Hughes DA; Ward DG
J Am Soc Mass Spectrom; 2016 Apr; 27(4):719-25. PubMed ID: 26797827
[TBL] [Abstract][Full Text] [Related]
19. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
20. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
